BioReg­num: The mir­a­cle drug sto­ry that just won’t die

The view from End­points

Eight years ago resver­a­trol was the mir­a­cle drug of the hour. Linked to pre­clin­i­cal ev­i­dence that it could ex­pand the life spans of mice, Glax­o­SmithK­line paid a whop­ping $720 mil­lion in cold, hard cash to get its hands on Sir­tris, the biotech start­up that promised to de­liv­er an an­ti-ag­ing mir­a­cle by turn­ing an in­gre­di­ent in red wine in­to a med­ical re­al­i­ty.

Queue the jokes about drink­ing more red wine for bet­ter health. This is the stuff head­lines are made of, and I was hap­py to par­tic­i­pate.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.